RxDoctor Payments Data

Marc Messineo, DO

Family Medicine · Babylon, NYNPI 1548232093

Payments from drug & device makers

$1,026in general payments, 2019–2025

Across 36 payments — averaging $28.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$279
  • Novo Nordisk$172
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$162
  • Esperion Therapeutics, Inc.$145
  • AstraZeneca$107
  • AbbVie$93
  • plus $68 from 3 others

What the payments were for

  • Food & beverage$1,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen3$279
Novo Nordisk11$172
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$162
Esperion Therapeutics, Inc.2$145
AstraZeneca5$107
AbbVie5$93
Lilly USA, LLC2$42
Baxter Healthcare1$26
Unified Women's Healthcare, LP5$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,026 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$173,623
Medicare patients
407
Services billed
3,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide103$106,484
OzempicSemaglutide102$96,064
JardianceEmpagliflozin38$52,006
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$44,022
JanuviaSitagliptin Phosphate22$34,519
EliquisApixaban49$33,517
LinzessLinaclotide39$28,049
VascepaIcosapent Ethyl16$10,022
XareltoRivaroxaban11$6,871
Varenicline Tartrate21$5,640
SynthroidLevothyroxine Sodium67$5,533
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$4,584
Valsartan187$4,220
Fentanyl32$3,898
Atorvastatin Calcium419$3,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$42$106,484103 claims
Novo NordiskOzempic$172$96,064102 claims
AbbVieLinzess, Synthroid$93$33,583106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →